KX2-391 (KX01) supplier|DC Chemicals

KX2-391 (KX01) supplier|DC Chemicals
DC Chemicals provides KX2-391 (KX01), other names: KX-01,kx 01, cas: 897016-82-9. In stock.

Contact: website: www.dcchemicals.com,
sales@dcchemicals.com,order@dcchemicals.com,info@dcchemicals.com,
Tel: +86-21-58447131;Fax:+86-21-61643352；

KX2-391 (KX01), the first clinical Src inhibitor (peptidomimetic class) that targets the peptide substrate site of Src, with GI50 of 9-60 nM in cancer cell lines.

KX2-391 (KX01), other names: KX-01,kx 01, cas: 897016-82-9, Molecule formular: C26H29N3O3, Molecule Weight: 431.53, Chemical name: N-benzyl-2-[5-[4-(2-morpholin-4-ylethoxy)phenyl]pyridin-2-yl]acetamide

KX2-391 is a Src inhibitor that is directed to the Src substrate pocket. KX2-391 shows steep dose-response curves against Huh7 (GI 50 = 9 nM), PLC/PRF/5 (GI 50 = 13 nM), Hep3B (GI 50 = 26 nM), and HepG2 (GI 50 = 60 nM), four hepatic cell cancer (HCC) cell lines. KX2-391 is found to inhibit certain leukemia cells that are resistant to current commercially available drugs, such as those derived from chronic leukemia cells with the T3151 mutation. KX2-391 is evaluated in engineered Src driven cell growth assays inNIH3T3/c-Src527F and SYF/c-Src527F cells and exhibits GI50 with 23 nM and 39 nM, respectively.
For the detailed information of KX2-391 (KX01), the solubility of KX2-391 (KX01) in water, the solubility of KX2-391 (KX01) in DMSO, the solubility of KX2-391 (KX01) in PBS buffer, the animal experiment (test) of  KX2-391 (KX01), the cell expriment (test) of KX2-391 (KX01), the in vivo, in vitro and clinical trial test of KX2-391 (KX01), the EC50, IC50,and affinity,of KX2-391 (KX01), Please contact DC Chemicals.